Search Results - "Cohan, Stanley L"
-
1
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
Published in Biomedicines (11-03-2019)“…Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade…”
Get full text
Journal Article -
2
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
Published in CNS drugs (01-07-2022)“…Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P 1 ) and 5 (S1P 5 ) modulator approved in the United States and the European Union as…”
Get full text
Journal Article -
3
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
Published in CNS drugs (01-07-2021)“…Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS)…”
Get full text
Journal Article -
4
Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses
Published in Neurology (13-08-2024)“…Race and ethnicity may influence the efficacy of disease-modifying therapies in patients with multiple sclerosis (MS). Incidence of MS in ethnically diverse…”
Get full text
Journal Article -
5
Advancing Care and Outcomes for African American Patients With Multiple Sclerosis
Published in Neurology (14-06-2022)“…Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS…”
Get full text
Journal Article -
6
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Published in Current medical research and opinion (01-02-2014)“…Abstract Background: Multiple sclerosis (MS) is a chronic inflammatory disease, affecting more than 2.5 million people worldwide with more 400,000 cases in the…”
Get full text
Journal Article -
7
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)
Published in Multiple sclerosis and related disorders (01-05-2018)“…Delayed-release dimethyl fumarate (DMF) may be a therapeutic option for patients with relapsing-remitting multiple sclerosis (RRMS) who are treated with…”
Get full text
Journal Article -
8
Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study
Published in ClinicoEconomics and outcomes research (01-01-2024)“…Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS). Utility values…”
Get full text
Journal Article -
9
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
Published in Neurology and therapy (01-06-2021)“…Introduction This post hoc subset analysis of RESPOND evaluated the effectiveness of dimethyl fumarate (DMF) 240 mg twice daily in patients with relapsing…”
Get full text
Journal Article -
10
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study
Published in Multiple sclerosis and related disorders (01-07-2023)“…Older age and longer disease duration (DD) may impact the effectiveness of disease-modifying therapies in patients with multiple sclerosis (MS). Siponimod is a…”
Get full text
Journal Article -
11
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis
Published in Blood (15-07-2000)“…Neuroserpin, a recently identified inhibitor of tissue-type plasminogen activator (tPA), is primarily localized to neurons within the central nervous system,…”
Get full text
Journal Article -
12
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
Published in Multiple sclerosis journal - experimental, translational and clinical (01-01-2019)“…Background Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need…”
Get full text
Journal Article -
13
Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis
Published in Multiple sclerosis (01-08-2005)“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text
Journal Article -
14
Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active SPMS from the Phase 3 EXPAND Study (4649)
Published in Neurology (13-04-2021)“…Abstract only…”
Get full text
Journal Article -
15
Advancing Care and Outcomes for African American Patients With Multiple Sclerosis
Published in Neurology (25-04-2022)“…Multiple sclerosis (MS) has historically been underdiagnosed and undertreated among African Americans. Recent evidence suggests that African Americans with MS…”
Get full text
Journal Article -
16
Safety and Tolerability of Conversion to Siponimod in Patients with Relapsing Multiple Sclerosis: Interim Results of the EXCHANGE Study (4598)
Published in Neurology (13-04-2021)“…Abstract only…”
Get full text
Journal Article -
17
Disutility of Cognitive Processing Speed Elicitation Study
Published in ClinicoEconomics and outcomes research (29-02-2024)“…Introduction: Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS)…”
Get full text
Journal Article -
18
Disutility of Cognitive Processing Speed
Published in ClinicoEconomics and outcomes research (29-02-2024)“…Introduction: Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS)…”
Get full text
Journal Article -
19
Effect of Siponimod on Disability in EXPAND Re-examined with Two New Subscales of the Expanded Disability Status Scale in Patients with SPMS (4051)
Published in Neurology (14-04-2020)“…Abstract only…”
Get full text
Journal Article -
20
2271 Safety and tolerability of conversion to siponimod with and without titration in patients with relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study
Published in BMJ neurology open (01-08-2022)“…ObjectivesEXCHANGE is a 6-month, open-label, single-arm trial of conversion to siponimod in patients with MS. Here we report interim analyses evaluating safety…”
Get full text
Journal Article